Active — Not RecruitingPhase 2

A Study of TCD601 in the Induction of Tolerance in de Novo Liver Transplantation

Sweden12 participantsStarted 2022-06-29

Plain-language summary

The purpose of this study is to evaluate if treatment with a siplizumab-based regimen can induce allogeneic tolerance in liver transplant recipients.

Who can participate

Age range18 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Able to understand the study requirements and provide written informed consent before and study assessment is performed * Adult subjects aged 18-70 receiving an ABO compatible deceased donor liver transplant * Male study subjects willing to maintain barrier contraception (condom) and agree not to father a child until 12 weeks after the last dose of MMF Exclusion Criteria: * Pregnant or nursing (lactating) women * Subjects with a history of TB or latent TB infection * Subjects with a history of cancer

What they're measuring

Number of Liver Transplant Recipients off of immunosuppression Therapy.

Timeframe: 30 months

Trial details

NCT IDNCT06019507

SponsorITB-Med LLC

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-06

View on ClinicalTrials.gov More Liver Transplantation trials